ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.254,18
1,03%
S&P 500
5.473,17
-0,25%
Dow Jones
39.134,76
0,77%
Euro vs US Dollar
1,07053
-0,02%
Bitcoin
64.640,84
-0,28%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Curis Inc (CRIS)

  7. Curis Inc (CRIS) News

CRIS Curis Inc

7,96
0,16 (2,05%)
20 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Curis Inc CRIS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,16 2,05% 7,96 22:00:10
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
7,75 7,5701 7,96 7,96 7,80
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
14.6.202422:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
23.5.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.5.202422:06EDGAR2Form 8-K - Current report
14.5.202422:04EDGAR2Form 8-K - Current report
14.5.202422:00PRNUSCuris Announces Additional Data from TakeAim Leukemia Study
10.5.202414:00PRNUSCuris to Present Updated Data from the TakeAim Leukemia..
07.5.202414:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.5.202414:02EDGAR2Form 8-K - Current report
07.5.202414:00PRNUSCuris Provides First Quarter 2024 Business Update
30.4.202414:00PRNUSCuris to Release First Quarter 2024 Financial Results and..
05.4.202413:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04.4.202413:30PRNUSCuris to Present at Upcoming Healthcare Conferences in April
12.2.202422:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08.2.202422:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
08.2.202422:27EDGAR2Form S-3 - Registration statement under Securities Act of..
08.2.202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08.2.202414:01EDGAR2Form 8-K - Current report
08.2.202414:00PRNUSCuris Provides Fourth Quarter 2023 Business Update
01.2.202414:00PRNUSCuris to Release Fourth Quarter 2023 Financial Results and..
11.1.202414:13EDGAR2Form 8-K - Current report
05.1.202414:00PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
21.12.202322:00EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
12.12.202314:00PRNUSCuris Announces Initial Combination Study Data from its..
11.12.202314:00PRNUSCuris Presented Clinical Data from the TakeAim Leukemia..
06.12.202314:00PRNUSCuris Announces Three Presentations at ASH
05.12.202314:00PRNUSCuris Enters into Agreement for Emavusertib / Pembrolizumab..
02.11.202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02.11.202313:01EDGAR2Form 8-K - Current report
02.11.202313:00PRNUSCuris Provides Third Quarter 2023 Business Update
26.10.202314:30PRNUSCuris to Release Third Quarter 2023 Financial Results and..
06.10.202314:56PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
28.9.202322:05EDGAR2Form 8-K/A - Current report: [Amend]
28.9.202314:54EDGAR2Form 8-K - Current report
12.9.202314:00PRNUSCuris Announces Date for the 2nd Symposium on IRAK4 in..
06.9.202314:13PRNUSCuris to Present at Upcoming Healthcare Conferences in..
18.8.202322:02EDGAR2Form DEF 14A - Other definitive proxy statements
04.8.202322:09EDGAR2Form PRE 14A - Other preliminary proxy statements
03.8.202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.8.202322:02EDGAR2Form 8-K - Current report
03.8.202322:01PRNUSCuris Provides Second Quarter 2023 Business Update
28.7.202300:25PRNUSCuris to Release Second Quarter 2023 Financial Results and..
06.7.202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06.7.202315:28EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

NASDAQ
CRIS
Curis
COIN
BNBBTC
Binance Coin
BIT
S28211
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten